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ABSTRACT 
Objective: The analysis of the cerebrospinal fluid (CSF) is an important tool for the diagnosis of neurological 
diseases. However, there is limited knowledge about the representativity of a single oligoclonal band (OCB) 
analysis for a neurological disaese during its clinical course. In this study we analysed the presence of OCB in 
the CSF of patients who underwent lumbar puncture more than once. 
Methods: We retrospectively analyzed anonymized data from serial 17002 CSF analyses done in the CSF 
laboratory of the Department of Neurology, University Hospital Zurich. We included cases with documented 
diagnosis in whom OCB were determined more than once. 
Results: We included 144 patients. Median time span between the first and the second OCB analysis was 274 
days (range: 1- 3533). The result of the second OCB analysis was identical in 109, and different in 35 cases 
(24%). 25 patients aquired, and 10 patients lost OCB over time. Three of 24 MS patients did not show OCB at 
the first CSF analysis, but in the second. In the entire group, newly ocurring OCB were often associated with 
new symptoms or occured after the acute phase of CNS infectious diseases, supposedly as consequence of the 
immune reaction. A loss of OCB was often associatd with remissions from diseases, e.g. during effective 
treatment. 
Conclusions: In patients with neurological diseases, both initially positive and negative OCB results may change 
over time, which often paralleles the clinical condition. Such variability must be taken into account for the 
interpretation of OCB results. 
 
INTRODUCTION 
The primary function of the cerebrospinal fluid (CSF) is protecting the central nervous system (CNS) from 
mechanic injury. Moreover, it is important for the homeostatic regulation, helps maintaining the intracerebral 
pressure at a constant level, circulates nutrients and rinses waste products from the brain parenchyma. In 
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humans, the majority of the CSF originates from the four choroid plexus in the ventricles, from parenchyma of 
the brain and of the spinal cord and from ependymal lining of the ventricels [1, 2]. CSF is constantly produced 
and mainly drained through cisternae, subarachnoid space and arachnoid villi into the venous blood. Transfer of 
proteins, such as albumin, antibodies or complement, from blood into CSF follows passive diffusion as a 
function of molecular size. Restriction of this transfer from blood into the CSF is called blood-CSF-barrier [3, 4]. 
While leukocytes can cross vessel walls to reach the perivascular space (PVS) as part of normal immune 
suveillance, their progression across the glia limitans into the brain parenchyma depends on perivascular antigen 
recognition inducing ectoenzymes such as metalloproteinases [5-7]. In neurological disorders, CSF analysis is an 
important tool for diagnosis [4]. Typical CSF signs of an acute CNS disease include an increased CSF cell count 
and an increased albumin CSF/ serum concentration quotient, the latter indicating an impairment of the blood-
CSF-barrier, as albumin is exclusively produced in the liver and thus can only occur in the CNS by passing the 
barrier. Immune reactions in the CNS include an intrathecal antibody synthesis of immunoglobulins originating 
from perivascular infiltrates of B-lymphocytes. Beneath the synthesis of specific antibodies in infectious 
diseases, the humoral immune response in the CNS may lead to polyspecific/ unspecific IgG/ IgA/ IgM patterns. 
Oligoclonal IgG detected as oligoclonal bands (OCB) upon isoelectric CSF focussing with or without 
corresponding OCB in the serum reflect an intrathecal humoral immune response with or without a 
corresponding systemic immune reaction and is often seen in autoimmune CNS inflammation including multiple 
sclerosis (MS), Sjögren syndrome, systemic lupus erythematosus (SLE) or neurosarcoidosis, but also in CNS 
infections [8-10]. Due to an improvement of MRI techniques, decreasing emphasis is placed on the value of CSF 
OCB in the diagnosis and study of MS [11]. Nevertheless, beneath the value of standard CSF analysis for the 
exclusion of differential diagnoses, OCB analysis may provide relevant information in the diagnostic process of 
autoimmune diseases. Positive OCB provide direct evidence of immune reactions in the CNS while imaging 
provides only indirect information. OCB are present in approx. 90-95% of MS patients, and thereby a positive 
result supports the diagnosis of MS against, for example, vascular lesions [12, 13]. Also within the group of 
autoimmune inflammatory diseases, the analysis of OCB may be helpful for differential diagnoses. For example, 
neuromyelitis optica (NMO) may resemble MS. OCB might be positive in NMO, but much less often than in 
MS, and therefore, the determination of OCB could be helpful for distinguishing MS from NMO [14,15].  
CSF analysis is usually performed for diagnostic purposes and by lumbar puncture (LP). As it is painful and 
invasive, it is only performed when clearly indicated. Therefore, longitudinal data on changes of OCB synthesis 
during the clnical course of an autoimmune disease are limited [16-18]. Aim of this study was to examine to 
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what extent OCB results change intraindividually over time and with which clinical conditions such changes 
might be associated.  
 
METHODS 
Patients 
We retrospectively analyzed 17002 anynomyzed serial lumbar punctures documented in the CSF database, 
Department of Neurology, University Hospital Zurich, after pseudonymisation. This database includes 
demographic (age, gender), clinical (confirmed or suspected diagnosis) and CSF data from 1992 on. Cases were 
included when ≥2 paired CSF and serum samples were analysed for OCB and the diagnosis was documented in 
the database.  
 
OCB definitions 
OCB were assessed by isoelectric focusing electrophoresis with anti-human-IgG and silver stain (PhastSystem, 
GE Healthcare, Heidelberg, Germany). OCB were identified by two experienced raters in consensus reading and, 
in rare case of differences, by the laboratoy supervisor. OCB negative (OCB neg) was defined as no OCB 
detection in CSF and serum (Fig 1a). OCB positive (OCB pos) was defined as ≥ 1 OCB in the CSF, but no OCB 
in corresponding serum (Fig 1a). OCB pos/pos was defined as ≥ 1 identic OCB in CSF and serum (Fig 1b). OCB 
pos+/pos was defined as identical OCB in CSF and serum plus additional OCB in the CSF (Fig 1b).  
 
RESULTS  
OCB analyses were done at least twice in 144 patients with confirmed diagnoses (2x in 115 patients, 3x in 16 
patients, 4x in 4 patients, 5x in 2 patients, 6x in 4 patients, 7x in 1 patient and 10x in 2 patients). There was no 
change in the result of OCB in 109 cases. In 16 of them, OCB were analysed more often than twice, and the 
results were also unchanged in those analyses. In 35 cases, OCB changed over time. In 13 of these cases, OCB 
were analysed more than twice.  
The group of patients with stable OCB included 43 women and 66 men. At the date of the first LP the age of 
individuals ranged from 18-80yr (median 44yr), at the second one from 18-81yr (median 47yr). The LP were 
done between April 1999 and July 2010. The time span between the LP ranged from 1- 3533 days (median 241 
days). Unchanged OCB neg appeared in 65 patients with mainly neurodegenerative and neurovascular diseases 
or other widespread diagnosis like headache or epilepsy and particularly without autoimmune or infectious CNS 
disease (table 1, column 1). An intrathecal only OCB synthesis (unchanged OCB pos) was repeatedly found in 
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41 individuals with mostly autoimmune or infectious CNS diseases including MS/ Clinically Isolated Syndrom 
(CIS), myelitis, neurosarcoidosis, vasculitis, HIV, meningitis/ meningoencephalitis and neurolues (table 1, 
column 2). A systemic OCB synthesis was repeatedly observed in three patients; each one with heamorrhage, 
motor neuron disease and normal pressure hydrocephalus (unchanged OCB pos/pos).  
The group of patients with newly appearing or with disappearing OCB included 21 women and 14 men (table 1, 
orange and blue columns). At the date of the first LP the age ranged from 16- 72yr (median 51yr) and at the 
second one from 21- 75yr (median 52yr). The LP were performed between July 1999 and July 2010. The time 
span between the LP ranged from 6- 2942 days (median 339 days); in the subgroup with newly emerging OCB 
from 6- 2942 days (median 329 days), and in the group with disappearing OCB from 53- 1049 (median 347 
days). 
The shift OCB neg-> OCB pos appeared in autoimmune, infectious and neurooncological diseases including 
MS/ CIS, NMO, chronic inflammatory demyelinating polyneuropathy (CIDP), myelitis, progressive multifocal 
leukencephalopathy (PML), neuroborreliosis, meningitis/ meningoencephalitis, primary CNS lymphoma. 
Noteworthy, in the patient with CIDP the additional diagnosis of possible MS was made between the two LP. 
The shift OCB neg-> OCB pos+/pos appeared in one MS patient. The change OCB neg-> OCB pos/pos 
occurred in autoimmune and neurodegenerative diseases (table 1, column 6). In the patient with dementia the 
diagnosis of an autoimmune disease (Basedow´s disease) was made in addition at the time of the second LP. The 
shift OCB pos-> OCB pos+/pos appeared in autoimmune diseases including MS and smoldering lymphoma with 
paraneoplastic polyradiculoneuropathy. The shift OCB pos-> OCB pos/pos was only seen in one patient with 
dementia. And finally, the shift OCB pos/pos-> OCB pos+/pos was only seen in multiple myeloma with 
emerging paraneoplastic polyneuropathy. 
In the group of patients with a loss of OCB, the shift OCB pos+/pos-> OCB pos was seen in one patient with 
autoimmune disease (collagenosis, M. Sjögren with CNS involvement). An immunosuppressive therapy with 
azathioprin had been established before the second LP. The shift OCB pos-> OCB neg occured in autoimmune 
and infectious diseases including collagenosis with CNS involvement, MS, neurosarcoidosis, breast cancer with 
paraneoplastic sensory polyneuropathy and leukoencephalopathy of unknown specification, myeloradiculitis and 
PML.  
In the patient with myeloradiculitis steroid therapy, and in the patient with collagenosis cyclophosphamide, 
hydroxychloroquin and steroids had been started between LP. Moreover, in  the MS patients, immunsuppressive 
therapy had been started between LP because of the additional dagnosis of CIDP and oligoarthritis with positive 
lupus serologic testing, respectively. Both patients with neurosarcoidosis had been treated with steroids between 
 5 
the LP, one with methotrexate in addition. The patient with PML suffered from chronic lymphocytic leukemia 
and had been treated with several chemotherapies and allogenic bone marrow transplantation between the two 
LP. 
In all of the 24 MS patients included in our anaysis, OCB were found positive at least once (tabel 1, column 2, 4-
7 and 11). Of the 24 MS patients, 19 had the diagnosis relapsing remitting MS (RRMS). In three of these RRMS 
patients, OCB were initially negative in the early phase of disease, but were detected in a subsequent analysis 
(table 2, column 3-5). Eight patients had the diagnosis CIS. Each three of them showed and did not show OCB in 
both LP (time span: 11- 482 days and 46-333 days, respectively), two had newly emerging OCB in the second 
LP (time span: 329- 1407).  
 
DISCUSSION  
Differential diagnoses of diseases associated with CSF IgG OCB include infections, systemic and CNS 
inflammatory disorders, peripheral neuropathies and others [10, 13, 16, 19-21].  
In clinical practice, OCB are often investigated in the diagnostic work-up of inflammatory CNS disorders, in 
particular MS. In our study, OCB were not only observed in MS patients, but also in patients with several other 
autoimmune and with infectious CNS diseases, as expected. However, it is noteworthy that OCB were found 
positive at least once in all of 24 MS patients. Time spans between an initially negative and the second, positive 
result ranged from 6.6- 60 months (mean 25 months). Thus, although presence of OCB in the CSF are no longer 
criterium for the diagnosis of RRMS and are only a facultative criterium for the diagnosis of primary progressive 
MS [11], our data suggest that it might be reasonable to do a second LP if OCB are negative at first in cases of 
suspected MS. If patients continue to have no intrathecal OCB production, it may become necessary to reconfirm 
an MS diagnosis.  
In one quarter of patients with repeated OCB analyses, the OCB result changed over time. A change to a positive 
result was often observed in infectious diseases. For example, in four patients with meningitis or meningo-
encephalitis, OCB where initially negative, but positive in the second LP 6-1471 days (mean 17 days) later, 
presumedly corresponding to a post-infectious immunological CNS response.  
Changes from a positive towards a negative OCB results were less frequent, observed in autoimmune disorders 
including MS, neurosarcoidosis and collagenosis as well as in PML. Interestingly, an immunsuppressive therapy 
had been established before the second LP in the patients with MS and collagenosis and in one of the patients 
with neurosacoidosis (table 1). These immunosuppressive therapies may be assumed as the reason for the 
dissapperance of OCB, which is unusual in MS patients [16,22]. In addition to immunosuppression, also the 
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treatment with natalizumab can lead to the dissappearance of OCB from the CSF of MS patients [17, 23]. In 
accordance, Harrer and collegues showed that CSF IgG production is reduced by natalizumab therapy in MS 
[23]. Fingolimod treatment also influences the number of lymphocytes in the CNS in neuroinflammatory 
diseases. Kowarik and collegues observed that treatment with fingolimod reduces the CSF leukocyte count in 
MS patients, but the B cell levels were more or less unchanged [24]. Consequently, CSF IgG levels and 
occurrence of OCB were not influenced. Our data suggest that immunosuppression reduces B-cell activity in the 
CNS in MS patients. It is tempting to speculate that a loss of OCB may be associated with response to 
immunosuppressive therapy of autoimmune diseases affecting the CNS. This is in line with other studies 
showing that the degree of humoral CNS immune response may be linked to the prognosis, i.e. the absence (or 
disappearance) of OCBs in MS patients may be assosiated with a better prognosis [22]. 
In 5 of 19 RRMS patients of our study population, OCB were initially negative or restricted to the CSF, but 
became positive or also detectable in the serum in the second investigation (table 2, column 3-6). In one of these 
5 patients, MS was diagnosed at the time of the second LP, and in another patient, the MS diagnosis was made 
later on. Further, one RRMS patient had initially positive OCB, became negative during natalizumab treatment, 
but positive again at PML onset (already published by Harrer 2013 [23]). This is in line with the oberservation of 
a switch from negative to positive OCB in another patient at PML onset (table 1, column 4) as well as stable 
positive OCB in a patient with known PML suffering from HIV (table 1, column 2). In the same context, 
Mazzarello found positive OCB in patients with PML [25].  
In conclusion, the analysis of CSF OCB still plays an important role in the diagnostic process of autoimmune 
diseases affecting the CNS, particularly MS. OCB results may change over time, which can be explained by 
clinical conditions. Such variability must be taken into account for the interpretation of OCB results.  
Limitations of our study are the retrospective analysis of data and the small number of cases per diagnosis. 
Furthermore, the second or further lumbar punctures were usually done for new clinical situations or for 
verification of uncertain diagnoses, which leads to selection bias favouring a higher amount of patients with 
changes in the OCB status.  
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Fig 1 Paired CSF and serum samples of OCB: (a) Two sets of paired CSF (C) and serum samples (S) showing 
the patterns of OCB pos, OCB neg and (b) two sets of paired CSF and serum sample illustrating the pattern of 
OCB pos/pos and OCB pos+/pos. Isoelectric focusing electrophoresis with anti-human-IgG and silver stain. The 
lower image quality can be explained because we work with microgels which subsequently were scanned in. 
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encephalitis 
   Myelo-
radiculitis 
3 1b; 1b+6          1 1c C1: new symptoms, 
follow-up, C11: 
follow-up (clinical 
improvement) 
   PML    1 1       1 1 C4: clinical 
deterioration 
   SSP  2            
   Neuro-
borreliosis 
2 6; 1c+6   1 1b+6         
   Neurolues 1 6 1 6          C1 and C2: follow-
up 
Neuro-
degenerative 
16 457 (8-2740) Dementia 3 1    1   1 1    C1: follow-up, 
clinical 
deterioration; C6: 
occurrence of an 
autoimmune disease 
at the date of the 
second LP; C8: 
follow-up, JC Virus 
positive at the date 
of 1. LP, negative at 
2. LP 
   Motor neuron 
disease 
1  1          
   MSA 1            
   Neuro- 3 1a+2           C1: follow-up 
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degenerative 
   Parkinson 
disease 
1            
   Spinal canal 
stenosis 
2            
   Spino-
cerebellar 
ataxia 
     1      C6: follow-up 
Neuro-
vascular 
6 806 (7-2699) Encephalo-
pathy vascular 
3 1          C1: follow-up, 
exclusion of NPH 
   Hemorrhage   1          
   Ischemia 1            
Neuro-
oncological 
6 52 (1-138) Lymphoma 
CNS 
   1        C4: follow-up/ 
diagnosis, clinical 
deterioration 
   Meningeoma 1            
   Metastasis/ 
Meningeosis 
carcinomatosa 
1 1           
   Tumour mass 1 1           
Others 27 181  
(88-274) 
Facial nerve 
paresis 
 2 1c+6          C2: follow-up, no 
clear clinical 
recovery 
  550  
(12-1614) 
Headache 3           C1: clinical 
deterioration 
  1052  
(13-2091) 
Mitochondrial 
disease 
2            
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  1643 Morbus Fahr 1            
  249  
(223-274) 
Myelopathy 2            
  17 Neuro-
psychiatric 
deficit 
1            
  8 NPH   1          
  1581 
(77-3533) 
Others 3 3         1 C11: follow-up 
  2482 PNP 1            
  1191  
(81-2300) 
Pseudotumor 
cerebri 
2            
  779 Restless legs 
Syndrome 
1            
  471  
(24-1541) 
Seizure 
disorder 
4           C1: another non-
convulsivus status 
epilepticus 
CIDP= chronic inflammatory demyelinating polyneuropathy, CIS= clinically isolated syndrome, GBS= Guillain Barré Syndrome, MS= multiple sclerosis, MSA= multisystem 
atrophy, NMO= Neuromyelitis optica Devic, NPH= normal pressure hydrocephalus, PML= progressive multifocal leukoencephalopathy, PNP= polyneuropathy, SSP= subacute 
sclerosing panencephalitis 
1: Under immunosuppressive therapy 
1a: Start immunosuppressive therapy between first and second CSF analysis  
 16 
1b: Steroid therapy 
1c: Steroid therapy between first and second CSF analysis 
2: Immunomodulating therapy (IVIG) between first and second CSF analysis 
2a: Immunomodulating therapy (IVIG) before first CSF analysis 
3: Autoimmune disease and immunosuppressive therapy 
4:  Under immunomodulating therapy (disease modifying therapy) 
4a: Start immunomodulating therapy (disease modifying therapy) between first and second CSF analysis 
5: Under immunomodulating therapy (disease modifying therapy) and immunsuppressive therapy 
6: Antiviral therapy/ antibiotic therapy 
7: Plasmapheresis between first and second CSF analysis 
 
Table 2 Overview of the change of OCBs in MS patients 
   Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 Column 7 
Diagnosis N  Time between CSF 
analysis (days), mean 
(range) 
Unchanged OCB  
neg 
Unchanged OCB 
pos 
OCB  
neg-> pos 
OCB  
neg-> pos+/ pos 
OCB  
neg-> pos/ pos 
OCB 
pos-> pos+/ pos 
OCB 
pos-> neg 
 
RRMS 19 953 
(64- 3256) 
 14 1 1 1 2  
PPMS 1 331  1      
SPMS 4 852  
(26- 2942) 
 1    1 2 
CIS 8 345  
(11-1407) 
3 3 2     
RRMS= relapsing-remitting multiple sclerosis, PPMS= primary progressive multiple sclerosis, SPMS= secondary progressive multiple sclerosis, CIS= clinically isolated 
syndrome 
